John P. Vasilakos0000-0002-1075-9665
John P. Vasilakos has 19+ years experience in the pharmaceutical and biotechnology industry focusing on the use of pathogen-associated molecular patterns (TLR agonists and beta glucans) as vaccine adjuvants and anticancer agents with particular attention on human innate immunity, dendritic cell biology, and antitumor and immune modulatory cytokines. Dr. Vasilakos has been a Senior Research Immunologist and Business Director for TLR Agonists at 3M Drug Delivery Systems, St. Paul Minnesota since February 2011. Previously, he was the Vice President of Immunology at Biothera in Eagan Minnesota from 2007 to 2011. He is an author of over 30 peer-reviewed publications and an Inventor of 12 patents. The majority of his publications have been on the effects of TLR7 and TLR8 activation on innate and adaptive immunity. More recently, he has published on beta glucans, which activate immune cells through Dectin-1 and CR3. Dr. Vasilakos did his postdoctoral training at Parke-Davis, Department of Cell Biology and Neurobiology, Ann Arbor, Michigan. He received his Ph.D. degree in molecular genetics, biochemistry, and microbiology from the University of Cincinnati, Cincinnati, Ohio, USA in 1993. He received an M.S. degree from the Wright State University in 1986 and a B.S. degree from the Miami University in 1984.
Biography Updated on 31 July 2011